查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1472188

疫苗佐劑市場：按類型、疾病和應用分類：2023-2032年全球機會分析和產業預測

Vaccine Adjuvants Market By Type (Immunostimulants, Vehicles and Mucosal Adjuvants), By Disease (Infectious Diseases, Others), By Application (Research, Commercial): Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3個工作天內

價格

2022年疫苗佐劑市場估值為10億美元，預計2032年將達15億美元，2023年至2032年複合年成長率為4%。佐劑是一種添加到疫苗接種中以增強和增加免疫系統對疫苗內抗原的反應的物質。疫苗接種中稱為抗原的成分會導致免疫系統產生抗體或其他免疫反應。佐劑透過促進更強、更持久和更強力的免疫反應來幫助提高疫苗的效率。

疫苗接種佐劑主要用於提高抗原引發免疫反應的能力，使其更強、更持久。佐劑透過多種策略來實現這一目標，包括促進免疫細胞的招募和活化、促進免疫細胞吸收抗原以及增強免疫系統對疫苗成分的整體識別。

疫苗佐劑市場-IMG1

佐劑允許疫苗製造商使用較低濃度的抗原，降低生產成本並提高疫苗接種安全性。此外，佐劑對於提高疫苗接種的有效性至關重要，特別是當需要強烈的免疫反應時，例如老年人或免疫系統受損的患者。此外，疫苗接種佐劑在添加到疫苗中之前要經過廣泛的測試，以確保安全性和有效性。在增強免疫反應和維持疫苗安全之間取得平衡是製造商和研究人員的目標。

由於多種原因，疫苗佐劑市場正在不斷擴大和開拓。對更安全、更有效的疫苗的日益成長的需求是這些問題背後的驅動力。感染疾病的日益普及和應對新出現的健康風險的持續努力推動了疫苗的研究和發展。為了提高疫苗接種的功效，佐劑變得越來越必要。

此外，世界各地政府和國際衛生組織正在擴大全球免疫計劃，推動了疫苗接種的需求。佐劑可增強免疫反應，因此對於大規模免疫計畫的成功至關重要。此外，治療性疫苗開發的增加是由於癌症等慢性病發生率的上升。佐劑在增強這些疫苗的功效方面發揮關鍵作用，推動了疫苗佐劑市場的擴大。

此外，隨著人口老化，罹患某些疾病的可能性也會增加。在為老年人接種疫苗時，佐劑變得更加重要，因為老年人的免疫反應可能較低。推動佐劑疫苗需求的另一個因素是這種人口趨勢。

免疫學和生物技術的進步促進了佐劑技術的發展和對免疫系統相互作用的理解的進步。這導致了更密集、更有效的助劑的開發，刺激了市場創新。公營和私營部門正在對疫苗和佐劑的研發進行大量投資。這些投資旨在解決未滿足的醫療需求並增強疫苗的整體功效和安全性，從而推動市場成長。

認知到佐劑在疫苗開發中的重要性，監管機構正在提供指導方針並支持將佐劑納入其中，以提高佐劑的採用率。這鼓勵製造商投資佐劑疫苗的開發和商業化，這也支持了市場成長。

疫苗佐劑市場按類型、疾病、應用和地區細分。按類型分類，市場分為免疫促效劑、載體和黏膜佐劑。活化片段進一步分為受體和其他類似的tor。按疾病分類，市場分為感染疾病和癌症。感染疾病市場進一步細分為肝炎和其他疾病。根據應用，市場分為研究市場和商業市場。

按地區分類，北美（美國、加拿大、墨西哥）、歐洲（德國、法國、英國、義大利、西班牙、其他歐洲國家地區）、亞太地區（印度、中國、日本、澳洲、韓國、其他亞太地區） ）、中美洲和南美洲（巴西、阿根廷、哥倫比亞、亞太地區其他地區）、中東美洲（海灣合作理事會、阿根廷、哥倫比亞、亞太地區其他地區）。

相關人員的主要利益

  • 該報告提供了 2022 年至 2032 年疫苗佐劑市場分析的細分市場、當前趨勢、估計和動態的定量分析，並確定了疫苗佐劑市場的潛在市場機會。
  • 我們提供市場研究以及與市場促進因素、市場限制和市場機會相關的資訊。
  • 波特的五力分析強調買家和供應商幫助相關人員做出利潤驅動的商業決策並加強供應商-買家網路的潛力。
  • 對疫苗佐劑市場區隔的詳細分析將有助於確定市場機會。
  • 每個地區的主要國家都根據其對全球市場的收益貢獻繪製了地圖。
  • 市場參與者定位有助於基準化分析，並提供對市場參與者當前地位的清晰了解。
  • 該報告包括對區域和全球疫苗佐劑市場趨勢、主要企業、細分市場、應用領域和市場成長策略的分析。

該報告可以客製化。

  • 監管指引
  • 策略建議
  • 針對客戶興趣的其他公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 公司簡介的擴充列表
  • 歷史市場資料
  • SWOT分析

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章疫苗佐劑市場：依類型

  • 概述
  • 免疫促效劑
    • 以活化類型分類的疫苗佐劑市場
  • 載體和黏膜佐劑

第5章疫苗佐劑市場：依疾病分類

  • 概述
  • 感染疾病
    • 按類型分類的感染疾病疫苗佐劑市場
  • 其他

第6章疫苗佐劑市場：依應用分類

  • 概述
  • 研究
  • 商業的

第7章疫苗佐劑市場：依地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲
    • 巴西
    • 哥倫比亞
    • 阿根廷
    • 其他拉丁美洲
  • 中東/非洲
    • Gcc
    • 南非
    • 北非
    • 其他中東/非洲

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第9章 公司簡介

  • Dynavax Technologies Corporation
  • Novovax
  • SEPPIC
  • Agenus Inc.
  • Aurorium
  • Adjuvatis
  • InvivoGen
  • GlaxoSmithKline plc
  • SPI Pharma, Inc.
  • Croda International Plc
Product Code: A01341

The vaccine adjuvants market was valued at $1 billion in 2022 and is estimated to reach $1.5 billion by 2032, exhibiting a CAGR of 4% from 2023 to 2032.Adjuvants are substances that are added to vaccinations in order to strengthen and increase the immune system's reaction to the antigens within the vaccine itself. The components of vaccinations called antigens are what cause the immune system to create antibodies and other immunological responses. Adjuvants assist to increase the efficiency of vaccines by fostering a stronger, longer-lasting, and more robust immune response.

Adjuvants for vaccinations are primarily used to improve an antigen's capacity to elicit an immune response, making it more robust and long-lasting. Adjuvants can accomplish this through a number of strategies, including encouraging immune cell recruitment and activation, boosting immune cell uptake of antigens, and strengthening the immune system's overall identification of the vaccine's components.

Vaccine Adjuvants Market - IMG1

Adjuvants enable vaccine manufacturers to employ lower concentrations of antigens, which lowers manufacturing costs and might improve vaccination safety. Furthermore, adjuvants are essential for enhancing the effectiveness of vaccinations, especially when a strong immune response is required, as in the case of elderly patients or those with compromised immune systems. Furthermore, adjuvants for vaccinations are put through extensive testing to make sure they are safe and effective before being added to vaccines. Achieving a balance between boosting the immune response and preserving vaccine safety is the target for the manufacturers and researchers.

The market for vaccine adjuvants is expanding and developing due to a number of causes. The growing need for safer and more effective vaccines is the driving force behind these issues. Vaccine research and development are driven by the increasing prevalence of infectious illnesses and the ongoing efforts to counter new health risks. Adjuvants are becoming more and more necessary to improve the effectiveness of vaccinations as more are being created.

Moreover, global immunization programs are being expanded by various governments globally and also by the international health organizations, which is driving up demand for vaccinations. Adjuvants are critical to the success of large-scale vaccination programs because they enhance the immune response. Also, a rise in the creation of therapeutic vaccines has been attributed to the rising incidence of chronic diseases like cancer. Adjuvants play a crucial role in augmenting the efficacy of these vaccines, hence fueling the vaccine adjuvants market expansion.

Moreover, as the population ages, there is a greater chance of developing several diseases. When creating vaccinations for older persons who could have a compromised immune response, adjuvants become more crucial. A further factor driving up demand for adjuvanted vaccinations is this demographic trend.

Technological developments in adjuvants and understanding of immune system interactions has improved as a result of developments in immunology and biotechnology. This has aided in the creation of adjuvants that are more focused and effective, spurring market innovation. Both public and private sectors are investing significantly in research and development of vaccines and adjuvants. These investments aim to address unmet medical needs and enhance the overall efficacy and safety profile of vaccines, thus boosting the market growth.

Regulatory agencies recognizing the importance of vaccine adjuvants in vaccine development provide guidelines and support for their incorporation which increases the adoption of adjuvants. This encourages manufacturers to invest in the development and commercialization of adjuvanted vaccines, which also drives the growth of the market.

The vaccine adjuvants market is segmented into type, disease, application, and region. On the basis of type, the market is bifurcated into immunostimulants and vehicles and mucosal adjuvants. The immunostimulants segment is further segmented into toll like receptor and others. As per disease, the market is divided into infectious diseases and cancer. The infectious diseases segment market is further segregated into hepatitis and others. On the basis of application, the market is classified into research and commercial.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (India, China, Japan, Australia, South Korea, and rest of Asia-Pacific), and Latin America (Brazil, Argentina, Colombia and rest of Latin America) and Middle East and Africa (GCC, South Africa, North Africa, and rest of LAMEA).

The major players that operate in the vaccine adjuvants market include Adjuvatis, Dynavax Technologies Corporation, GSK, Croda International, Novovax, SEPPIC, Agenus Inc, Invivogen, SPI Pharma, and Aurorium. These key players have adopted key strategies such as partnership and business expansion to expand their product portfolio.

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vaccine adjuvants market analysis from 2022 to 2032 to identify the prevailing vaccine adjuvants market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the vaccine adjuvants market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global vaccine adjuvants market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Strategic Recommendations
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Type

  • Immunostimulants
    • Type
    • Toll-like receptor
    • Others
  • Vehicles and Mucosal Adjuvants

By Disease

  • Infectious Diseases
    • Type
    • Hepatitis
    • Others
  • Others

By Application

  • Research
  • Commercial

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Colombia
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • Gcc
    • South Africa
    • North Africa
    • Rest of Middle East And Africa

Key Market Players:

    • Dynavax Technologies Corporation
    • Novovax
    • Agenus Inc.
    • Adjuvatis
    • Aurorium
    • InvivoGen
    • SEPPIC
    • GlaxoSmithKline plc
    • SPI Pharma, Inc.
    • Croda International Plc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: VACCINE ADJUVANTS MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Immunostimulants
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. Immunostimulants Vaccine Adjuvants Market by Type
  • 4.3. Vehicles and Mucosal Adjuvants
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: VACCINE ADJUVANTS MARKET, BY DISEASE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Infectious Diseases
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
    • 5.2.4. Infectious Diseases Vaccine Adjuvants Market by Type
  • 5.3. Others
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: VACCINE ADJUVANTS MARKET, BY APPLICATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Research
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Commercial
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country

CHAPTER 7: VACCINE ADJUVANTS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Disease
    • 7.2.4. Market size and forecast, by Application
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Type
      • 7.2.5.1.2. Market size and forecast, by Disease
      • 7.2.5.1.3. Market size and forecast, by Application
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Type
      • 7.2.5.2.2. Market size and forecast, by Disease
      • 7.2.5.2.3. Market size and forecast, by Application
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Type
      • 7.2.5.3.2. Market size and forecast, by Disease
      • 7.2.5.3.3. Market size and forecast, by Application
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Disease
    • 7.3.4. Market size and forecast, by Application
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Type
      • 7.3.5.1.2. Market size and forecast, by Disease
      • 7.3.5.1.3. Market size and forecast, by Application
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Type
      • 7.3.5.2.2. Market size and forecast, by Disease
      • 7.3.5.2.3. Market size and forecast, by Application
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Type
      • 7.3.5.3.2. Market size and forecast, by Disease
      • 7.3.5.3.3. Market size and forecast, by Application
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Type
      • 7.3.5.4.2. Market size and forecast, by Disease
      • 7.3.5.4.3. Market size and forecast, by Application
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Type
      • 7.3.5.5.2. Market size and forecast, by Disease
      • 7.3.5.5.3. Market size and forecast, by Application
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Type
      • 7.3.5.6.2. Market size and forecast, by Disease
      • 7.3.5.6.3. Market size and forecast, by Application
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Disease
    • 7.4.4. Market size and forecast, by Application
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Type
      • 7.4.5.1.2. Market size and forecast, by Disease
      • 7.4.5.1.3. Market size and forecast, by Application
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Type
      • 7.4.5.2.2. Market size and forecast, by Disease
      • 7.4.5.2.3. Market size and forecast, by Application
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Type
      • 7.4.5.3.2. Market size and forecast, by Disease
      • 7.4.5.3.3. Market size and forecast, by Application
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Type
      • 7.4.5.4.2. Market size and forecast, by Disease
      • 7.4.5.4.3. Market size and forecast, by Application
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Type
      • 7.4.5.5.2. Market size and forecast, by Disease
      • 7.4.5.5.3. Market size and forecast, by Application
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Type
      • 7.4.5.6.2. Market size and forecast, by Disease
      • 7.4.5.6.3. Market size and forecast, by Application
  • 7.5. Latin America
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Disease
    • 7.5.4. Market size and forecast, by Application
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Type
      • 7.5.5.1.2. Market size and forecast, by Disease
      • 7.5.5.1.3. Market size and forecast, by Application
      • 7.5.5.2. Colombia
      • 7.5.5.2.1. Market size and forecast, by Type
      • 7.5.5.2.2. Market size and forecast, by Disease
      • 7.5.5.2.3. Market size and forecast, by Application
      • 7.5.5.3. Argentina
      • 7.5.5.3.1. Market size and forecast, by Type
      • 7.5.5.3.2. Market size and forecast, by Disease
      • 7.5.5.3.3. Market size and forecast, by Application
      • 7.5.5.4. Rest of Latin America
      • 7.5.5.4.1. Market size and forecast, by Type
      • 7.5.5.4.2. Market size and forecast, by Disease
      • 7.5.5.4.3. Market size and forecast, by Application
  • 7.6. Middle East and Africa
    • 7.6.1. Key market trends, growth factors and opportunities
    • 7.6.2. Market size and forecast, by Type
    • 7.6.3. Market size and forecast, by Disease
    • 7.6.4. Market size and forecast, by Application
    • 7.6.5. Market size and forecast, by country
      • 7.6.5.1. Gcc
      • 7.6.5.1.1. Market size and forecast, by Type
      • 7.6.5.1.2. Market size and forecast, by Disease
      • 7.6.5.1.3. Market size and forecast, by Application
      • 7.6.5.2. South Africa
      • 7.6.5.2.1. Market size and forecast, by Type
      • 7.6.5.2.2. Market size and forecast, by Disease
      • 7.6.5.2.3. Market size and forecast, by Application
      • 7.6.5.3. North Africa
      • 7.6.5.3.1. Market size and forecast, by Type
      • 7.6.5.3.2. Market size and forecast, by Disease
      • 7.6.5.3.3. Market size and forecast, by Application
      • 7.6.5.4. Rest of Middle East And Africa
      • 7.6.5.4.1. Market size and forecast, by Type
      • 7.6.5.4.2. Market size and forecast, by Disease
      • 7.6.5.4.3. Market size and forecast, by Application

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Dynavax Technologies Corporation
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Novovax
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. SEPPIC
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
  • 9.4. Agenus Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Aurorium
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
  • 9.6. Adjuvatis
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
  • 9.7. InvivoGen
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
  • 9.8. GlaxoSmithKline plc
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. SPI Pharma, Inc.
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
  • 9.10. Croda International Plc
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot

LIST OF TABLES

  • TABLE 01. GLOBAL VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 02. VACCINE ADJUVANTS MARKET FOR IMMUNOSTIMULANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. GLOBAL IMMUNOSTIMULANTS VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 04. VACCINE ADJUVANTS MARKET FOR VEHICLES AND MUCOSAL ADJUVANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 06. VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. GLOBAL INFECTIOUS DISEASES VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 08. VACCINE ADJUVANTS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 10. VACCINE ADJUVANTS MARKET FOR RESEARCH, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. VACCINE ADJUVANTS MARKET FOR COMMERCIAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. VACCINE ADJUVANTS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 17. U.S. VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 18. U.S. VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 19. U.S. VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 20. CANADA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 21. CANADA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 22. CANADA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. MEXICO VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 30. GERMANY VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 36. UK VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 37. UK VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 38. UK VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 39. ITALY VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 40. ITALY VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 41. ITALY VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. REST OF EUROPE VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 52. JAPAN VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 55. CHINA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 56. CHINA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 57. CHINA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 58. INDIA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 59. INDIA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 60. INDIA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 61. AUSTRALIA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 62. AUSTRALIA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH KOREA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 67. REST OF ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 70. LATIN AMERICA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 71. LATIN AMERICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 72. LATIN AMERICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 73. LATIN AMERICA VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 74. BRAZIL VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 75. BRAZIL VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 77. COLOMBIA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 78. COLOMBIA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 79. COLOMBIA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 80. ARGENTINA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 81. ARGENTINA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 82. ARGENTINA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 83. REST OF LATIN AMERICA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 84. REST OF LATIN AMERICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LATIN AMERICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 86. MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 87. MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 88. MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 89. MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 90. GCC VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 91. GCC VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 92. GCC VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 93. SOUTH AFRICA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH AFRICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH AFRICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 96. NORTH AFRICA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 97. NORTH AFRICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 98. NORTH AFRICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 99. REST OF MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 100. REST OF MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY DISEASE, 2022-2032 ($MILLION)
  • TABLE 101. REST OF MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 102. DYNAVAX TECHNOLOGIES CORPORATION: KEY EXECUTIVES
  • TABLE 103. DYNAVAX TECHNOLOGIES CORPORATION: COMPANY SNAPSHOT
  • TABLE 104. DYNAVAX TECHNOLOGIES CORPORATION: PRODUCT SEGMENTS
  • TABLE 105. DYNAVAX TECHNOLOGIES CORPORATION: PRODUCT PORTFOLIO
  • TABLE 106. DYNAVAX TECHNOLOGIES CORPORATION: KEY STRATERGIES
  • TABLE 107. NOVOVAX: KEY EXECUTIVES
  • TABLE 108. NOVOVAX: COMPANY SNAPSHOT
  • TABLE 109. NOVOVAX: PRODUCT SEGMENTS
  • TABLE 110. NOVOVAX: PRODUCT PORTFOLIO
  • TABLE 111. SEPPIC: KEY EXECUTIVES
  • TABLE 112. SEPPIC: COMPANY SNAPSHOT
  • TABLE 113. AGENUS INC.: KEY EXECUTIVES
  • TABLE 114. AGENUS INC.: COMPANY SNAPSHOT
  • TABLE 115. AGENUS INC.: PRODUCT SEGMENTS
  • TABLE 116. AGENUS INC.: PRODUCT PORTFOLIO
  • TABLE 117. AGENUS INC.: KEY STRATERGIES
  • TABLE 118. AURORIUM: KEY EXECUTIVES
  • TABLE 119. AURORIUM: COMPANY SNAPSHOT
  • TABLE 120. AURORIUM: PRODUCT SEGMENTS
  • TABLE 121. AURORIUM: PRODUCT PORTFOLIO
  • TABLE 122. ADJUVATIS: KEY EXECUTIVES
  • TABLE 123. ADJUVATIS: COMPANY SNAPSHOT
  • TABLE 124. ADJUVATIS: PRODUCT SEGMENTS
  • TABLE 125. ADJUVATIS: SERVICE SEGMENTS
  • TABLE 126. ADJUVATIS: PRODUCT PORTFOLIO
  • TABLE 127. INVIVOGEN: KEY EXECUTIVES
  • TABLE 128. INVIVOGEN: COMPANY SNAPSHOT
  • TABLE 129. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 130. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 131. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 132. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 133. GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 134. SPI PHARMA, INC.: KEY EXECUTIVES
  • TABLE 135. SPI PHARMA, INC.: COMPANY SNAPSHOT
  • TABLE 136. CRODA INTERNATIONAL PLC: KEY EXECUTIVES
  • TABLE 137. CRODA INTERNATIONAL PLC: COMPANY SNAPSHOT

LIST OF FIGURES

  • FIGURE 01. VACCINE ADJUVANTS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF VACCINE ADJUVANTS MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN VACCINE ADJUVANTS MARKET
  • FIGURE 04. TOP INVESTMENT POCKETS IN VACCINE ADJUVANTS MARKET (2023-2032)
  • FIGURE 05. BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. BARGAINING POWER OF BUYERS
  • FIGURE 07. THREAT OF SUBSTITUTION
  • FIGURE 08. THREAT OF SUBSTITUTION
  • FIGURE 09. COMPETITIVE RIVALRY
  • FIGURE 10. GLOBAL VACCINE ADJUVANTS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. VACCINE ADJUVANTS MARKET, BY TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF VACCINE ADJUVANTS MARKET FOR IMMUNOSTIMULANTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF VACCINE ADJUVANTS MARKET FOR VEHICLES AND MUCOSAL ADJUVANTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. VACCINE ADJUVANTS MARKET, BY DISEASE, 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF VACCINE ADJUVANTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF VACCINE ADJUVANTS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. VACCINE ADJUVANTS MARKET, BY APPLICATION, 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF VACCINE ADJUVANTS MARKET FOR RESEARCH, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF VACCINE ADJUVANTS MARKET FOR COMMERCIAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. VACCINE ADJUVANTS MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 21. U.S. VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 22. CANADA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. MEXICO VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. GERMANY VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. FRANCE VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. UK VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. ITALY VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. SPAIN VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. REST OF EUROPE VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. JAPAN VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. CHINA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. INDIA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. AUSTRALIA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. SOUTH KOREA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. REST OF ASIA-PACIFIC VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. BRAZIL VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. COLOMBIA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. ARGENTINA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. REST OF LATIN AMERICA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. GCC VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. SOUTH AFRICA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. NORTH AFRICA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. REST OF MIDDLE EAST AND AFRICA VACCINE ADJUVANTS MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 45. COMPETITIVE DASHBOARD
  • FIGURE 46. COMPETITIVE HEATMAP: VACCINE ADJUVANTS MARKET
  • FIGURE 47. TOP PLAYER POSITIONING, 2022
  • FIGURE 48. DYNAVAX TECHNOLOGIES CORPORATION: NET REVENUE, 2019-2022 ($MILLION)
  • FIGURE 49. DYNAVAX TECHNOLOGIES CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 50. DYNAVAX TECHNOLOGIES CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 51. NOVOVAX: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. AGENUS INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 53. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)